| Revenue | DKK 315K | -27% |
| EBITDA | DKK -52K | -309% |
| Net profit | DKK 1K | +101% |
| Total assets | DKK 1,6M | -3% |
| Equity | DKK 1,5M | +0% |
| Employees | 2 | — |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 481 | 783 | 488 | 432 | 315 |
| Staff expenses | -175 | -281 | -316 | -444 | -367 |
| EBITDA | 306 | 502 | 173 | -13 | -52 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 306 | 502 | 173 | -13 | -52 |
| Net financials | -33 | 25 | 8 | -114 | 53 |
| Profit before tax | 274 | 527 | 180 | -127 | 2 |
| Tax | 60 | 116 | 40 | -28 | 0 |
| Net profit | 213 | 411 | 140 | -99 | 1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.149 | 2.673 | 2.085 | 1.674 | 1.623 |
| Equity | 1.847 | 2.258 | 1.798 | 1.499 | 1.500 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 303 | 415 | 287 | 174 | 122 |
| Total debt | 303 | 415 | 287 | 174 | 122 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
BA Founder | Founder | 2000 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (5) | ||
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2011 – 2024 | |
| Board of Directors | 2000 – 2011 | |
| Chairman | 2020 – 2025 | |
| Board of Directors | 2000 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50–66.65% | 50–66.65% | 2016 | |
| Company | 100% | 100% | 2024 | |
| Individual | 50–66.65% | 50–66.65% | 2021 | |
| Individual | 15–19.99% | 15–19.99% | 2020 | |
| Company | 50–66.65% | 50–66.65% | 2008 |
| Person | Role here | Other companies |
|---|---|---|
| Biolab AS | Founder | 0 companies |
| Niklas Rønnow Nygaard | Board of Directors | 0 companies |
| Per Egil Sørensen | Board of Directors | 0 companies |
| Henrik Ramstad | Board of Directors | 0 companies |
| Tom Nygaard | Chairman | 0 companies |
| Conny Nygaard | Board of Directors | 0 companies |